Sigma Planning Corp Reduces Position in uniQure (NASDAQ:QURE)

Sigma Planning Corp trimmed its position in uniQure (NASDAQ:QURE) by 51.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 28,745 shares of the biotechnology company’s stock after selling 30,510 shares during the period. Sigma Planning Corp’s holdings in uniQure were worth $195,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 683 Capital Management LLC increased its position in shares of uniQure by 21.6% in the third quarter. 683 Capital Management LLC now owns 1,575,000 shares of the biotechnology company’s stock valued at $10,568,000 after acquiring an additional 280,000 shares during the period. Barclays PLC grew its stake in shares of uniQure by 527.8% in the third quarter. Barclays PLC now owns 989,562 shares of the biotechnology company’s stock worth $6,641,000 after purchasing an additional 831,929 shares during the last quarter. Citigroup Inc. increased its holdings in uniQure by 667.9% during the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock valued at $5,143,000 after purchasing an additional 666,696 shares during the period. Algert Global LLC raised its position in uniQure by 237.6% during the 3rd quarter. Algert Global LLC now owns 414,241 shares of the biotechnology company’s stock valued at $2,780,000 after purchasing an additional 291,541 shares during the last quarter. Finally, abrdn plc purchased a new stake in uniQure in the 4th quarter worth approximately $2,711,000. 78.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on QURE. Mizuho decreased their target price on uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Monday, March 4th. The Goldman Sachs Group cut shares of uniQure from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Friday, March 1st. HC Wainwright lowered their price objective on shares of uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a report on Friday, March 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 target price on shares of uniQure in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $32.00.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 27,904 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.35, for a total transaction of $177,190.40. Following the transaction, the chief executive officer now directly owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Christian Klemt sold 15,906 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.38, for a total transaction of $101,480.28. Following the transaction, the chief financial officer now directly owns 116,948 shares of the company’s stock, valued at approximately $746,128.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the sale, the chief executive officer now directly owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,265 shares of company stock valued at $339,845. Corporate insiders own 4.05% of the company’s stock.

uniQure Trading Down 3.1 %

QURE opened at $4.39 on Tuesday. uniQure has a 1 year low of $4.35 and a 1 year high of $22.48. The stock has a 50-day moving average price of $5.24 and a 200-day moving average price of $5.96. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.01. The firm had revenue of $6.69 million for the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. On average, equities research analysts anticipate that uniQure will post -4.49 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.